ASHP -- BETHESDA, MD 11 May 2009—The development of a gastrointestinal perforation, a severe skin condition, or eye pain is cause for stopping a patient's erlotinib therapy, OSI Pharmaceuticals Inc. and Genentech Inc. said in a letter (PDF) distributed May 8 by FDA's MedWatch program.
